Efficacy safety and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr81 trial
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Description
Keywords
Citation
WOS